Format

Send to

Choose Destination
Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.

Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.

Author information

1
Department of Pharmaceutical Chemistry, University of California, San Francisco, California.
2
Kidney Transplant Service, University of California, San Francisco, California.
3
AbbVie, Renal Discovery, Chicago, Illinois.
4
Department of Pathology, University of California, San Francisco, California.
5
The Finsen Laboratory, Copenhagen University Hospital/Biotech Research & Innovation Centre, Copenhagen, Denmark.
6
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
7
Department of Epidemiology and Biostatistics, University of California, San Francisco, California.

Abstract

BACKGROUND:

We investigated circulating levels of individual soluble urokinase plasminogen activation receptor (suPAR) forms to determine if specific circulating fragments of suPAR (II-III) and (I) can better serve as clinical biomarkers for focal segmental glomerulosclerosis (FSGS) and the risk of recurrence after transplantation.

MATERIALS AND METHODS:

Serum levels of intact suPAR and its cleaved forms were measured with two assays, ELISA and TR-FIA.

RESULTS:

suPAR levels in healthy controls were significantly lower than those who had glomerular diseases but were not significantly different between FSGS patients and glomerular controls. Intact suPAR (I-II-III) levels were noted to be elevated in glomerular diseases including FSGS. uPAR fragment (I) levels measured with the TR-FIA 4 assay were significantly higher in FSGS (695.4 + 91.29 pMol/L) than glomerular controls (239.1 + 40.45 pMol/L, P = 0.001). However, suPAR(I) levels were not significantly different between recurrent FSGS and nonrecurrent FSGS patients.

CONCLUSION:

Our analysis of suPAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR-FIA assay results suggest that uPAR(I) is a potential biomarker for FSGS but not of its recurrence.

KEYWORDS:

focal segmental glomerulosclerosis; suPAR; suPAR forms; uPAR (I)

PMID:
30689221
DOI:
10.1111/ctr.13487

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center